BGB-16673
Instead of blocking BTK, this pill destroys it, so it works even when the enzyme has mutated to escape every inhibitor.
Chimeric degradation-activating compound recruiting an E3 ligase to BTK. CaDAnCe-101 (phase 1, relapsed CLL/SLL after covalent BTKi, many with BTK mutations): ORR 86% in 66 patients with a manageable profile (fatigue, bruising, diarrhoea, neutropenia), updated at EHA 2026. Phase 3 CaDAnCe-304 (~500 patients) compares BGB-16673 with pirtobrutinib after covalent BTKi. The first BTK degrader in phase 3.
1.BGB-16673 bridges BTK and an E3 ubiquitin ligase
- Route
- Oral
- Schedule
- 200 mg once daily (recommended phase 2 dose), continuous
- Monitoring
- Neutropenia, infections, bleeding
Compare all products across the US, EU, UK, Japan, China and Australia →
| Adverse event | Any grade | Grade 3+ |
|---|---|---|
| Fatigue | 25% | — |
| Contusion/bruising | 25% | — |
| Neutropenia | 25% | — |
≥25% in CaDAnCe-101. Rates read from the source. Blank cells mean the figure was not sourced, not that it is zero.
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"BGB-16673" OR ABSTRACT:"BGB-16673") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BGB-16673, not a curated reading list.